Shramova Elena, Proshkina Galina, Shipunova Victoria, Ryabova Anastasia, Kamyshinsky Roman, Konevega Andrey, Schulga Aleksey, Konovalova Elena, Telegin Georgij, Deyev Sergey
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya Street 16/10, 117997 Moscow, Russia.
Prokhorov General Physics Institute, Russian Academy of Sciences, Vavilova Street 38, 119991 Moscow, Russia.
Cancers (Basel). 2020 Oct 16;12(10):3014. doi: 10.3390/cancers12103014.
We report here a combined anti-cancer therapy directed toward HER2 and EpCAM, common tumor-associated antigens of breast cancer cells. The combined therapeutic effect is achieved owing to two highly toxic proteins-a low immunogenic variant of exotoxin A and ribonuclease Barnase from . The delivery of toxins to cancer cells was carried out by targeting designed ankyrin repeat proteins (DARPins). We have shown that both target agents efficiently accumulate in the tumor. Simultaneous treatment of breast carcinoma-bearing mice with anti-EpCAM fusion toxin based on LoPE and HER2-specific liposomes loaded with Barnase leads to concurrent elimination of primary tumor and metastases. Monotherapy with anti-HER2- or anti-EpCAM-toxins did not produce a comparable effect on metastases. The proposed approach can be considered as a promising strategy for significant improvement of cancer therapy.
我们在此报告一种针对HER2和EpCAM这两种乳腺癌细胞常见肿瘤相关抗原的联合抗癌疗法。联合治疗效果的实现得益于两种剧毒蛋白——外毒素A的低免疫原性变体和来自芽孢杆菌的核糖核酸酶Barnase。通过靶向设计锚蛋白重复序列蛋白(DARPins)将毒素递送至癌细胞。我们已经表明,两种靶向剂都能有效地在肿瘤中积累。基于低聚肽(LoPE)的抗EpCAM融合毒素和负载Barnase的HER2特异性脂质体同时治疗荷乳腺癌小鼠,可导致原发性肿瘤和转移灶同时消除。用抗HER2或抗EpCAM毒素进行单一疗法对转移灶没有产生类似的效果。所提出的方法可被视为显著改善癌症治疗的一种有前景的策略。